Intracoronary Thrombus A Sticky Problem⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology. by Cohen, Mauricio G.
EI
A
M
M
M
t
o
m
c
m
c
c
t
o
n
o
t
o
a
c
o
h
c
i
t
t
c
i
a
d
v
s
3
C
t
s
l
w
E
v
o
u
a
z
l
r
e
e
t
e
v
u
l
d
e
s
(
a
(
r
i
i
c
a
C
t
p
p
i
d
o
w
d
e
a
r
D
4
D
p
i
m
o
t
r
*
a
t
M
a
I
S
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 3 , N O . 9 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 0 . 0 8 . 0 0 4DITORIAL COMMENT
ntracoronary Thrombus
Sticky Problem*
auricio G. Cohen, MD
iami, Florida
ore than 3 decades have passed since the demonstration of
he pivotal role of coronary thrombosis in the pathophysi-
logic mechanism of acute coronary syndromes. Since then,
ost therapeutic interventions have aimed at dissolving the
lot overlying the culprit plaque by pharmacological or
echanical means (1). Although fibrinolytic therapy be-
ame the standard of care for ST-segment elevation myo-
ardial infarction (STEMI) patients, in which a fibrin-rich
hrombus is responsible for complete epicardial coronary
cclusion, its use in non–ST-segment elevation acute coro-
ary syndrome (NSTACS) has been associated with equiv-
cal and, at times, adverse results. In such cases, when the
hrombus is more labile, rich in platelets, and incompletely
cclusive, potent antiplatelet agents such as thienopyridines
nd glycoprotein (GP) IIb/IIIa inhibitors are currently the
ornerstone therapy (2). Concurrently, technological devel-
pments gave the necessary tools to cardiologists to manage
igh-risk patients with the most challenging lesions in the
atheterization laboratory. Primary percutaneous coronary
ntervention (PCI) and early invasive management became
he standard of care for STEMI and NSTACS, respec-
ively, in tertiary care centers (3,4).
See page 937
The NSTACS patients with high Thrombolysis In Myo-
ardial Infarction (TIMI) risk scores are more likely to have
ntracoronary visible thrombus, impaired angiographic flow,
nd greater extent of coronary atherosclerosis. Observational
ata demonstrated a stepwise increase in the prevalence of
isible angiographic thrombus with increasing TIMI risk
cores (30% with TIMI score 0 to 2, 36% with TIMI score
to 4, and 41% with TIMI score 5 to 7, p  0.001) (5).
oronary thrombus is a significant challenge in the cathe-
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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peakers’ Bureau for Medtronic, Inc. and Terumo Medical.erization laboratory and is identified as a filling defect
urrounded by contrast or staining at the site of a high-grade
esion or total occlusion or upward convexity or irregularity
ithout vessel tapering at the site of an abrupt occlusion.
arly angiographic studies revealed that the presence of
isible thrombus was the strongest predictor of poor clinical
utcomes, such as death, myocardial infarction, and need for
rgent revascularization after PCI (6). These increased
dverse event rates are likely a consequence of distal emboli-
ation and no-reflow, which correlate with higher incidence of
eft ventricular systolic dysfunction, malignant ventricular ar-
hythmias, heart failure, and cardiac rupture. Macro- or micro-
mbolization in a coronary territory can cause capillary damage,
ndothelial swelling, myocyte edema, and neutrophil infiltra-
ion resulting in inadequate myocardial perfusion without
picardial vessel obstruction (7,8).
In this issue of JACC: Cardiovascular Interventions, Srini-
asan et al. (9) report the outcomes of 6,227 patients
ndergoing PCI in native vessels with thrombus-containing
esions at a single high-volume center. Data were broken
own according to 3 periods in interventional cardiology: an
arly stent era with Palmaz-Schatz and Gianturco-Roubin
tents (January 1990 to December 1996), a bare-metal stent
BMS) era with more flexible and deliverable metal stents
nd routine use of intravenous and oral antiplatelet agents
January 1997 to March 2003), and a period intended to
epresent current practice with a rapid and sustained uptake
n drug-eluting stent (DES) use, mostly for “off-label”
ndications (April 2003 to August 2006). An important
aveat is that after the presentation of controversial data
bout long-term safety of DES at the European Congress of
ardiology in September 2006, DES use dropped sharply in
he U.S. (10). Furthermore, the data presented in this study
recede the U.S. Food and Drug Administration advisory
anel meeting on DES safety and the recommendations
ssued by professional associations regarding the risks of
ual antiplatelet therapy discontinuation within 12 months
f stent implantation (11).
A previous publication of the Mayo Clinic experience
ith PCI in thrombotic lesions showed improved proce-
ural success but no differences in major adverse cardiac
vents (MACE) among patients treated during the early
nd late BMS eras (before and after 1996) (12). The current
eport confirms previous findings and extends the results to
ES-treated patients. Procedural success improved from
3%, in the early stent era, to 85% to 86% in the BMS and
ES eras, despite the increasing prevalence of more com-
lex and flow-limiting lesions. Explanations include the steep
ncrease in use of GP IIb/IIIa inhibitors from 8% to approxi-
ately 80% and stents from 10% to more than 90% that
ccurred after 1996, with a modest uptake of mechanical
hrombectomy devices of 5% to 6%, mostly at the expense of
heolytic devices and 1% use of manual aspiration catheters.
lthough the authors should be commended for their thor-
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Editorial Comment
948ugh analysis, these data represent the practice pattern in a
ingle institution up to calendar year 2006, and they might not
ecessarily reflect more recent trends.
The adjunctive use of GP IIb/IIIa inhibitors during
rimary PCI is associated with a significant reduction in
eath and reinfarction rates (13). In NSTACS, upstream
se of GP IIb/IIIa inhibitors reduces thrombus burden and
mproves coronary flow (14). However, after the recognition
f bleeding in the early 2000s, as a determinant of major
dverse outcomes, the use of GP2b3a inhibitors dropped
ubstantially in the U.S. (15). During the same period,
linical trials demonstrated that bivalirudin provides stable
nticoagulation during PCI with less bleeding than heparin
nd GP IIb/IIIa inhibitors (16). Furthermore, the unex-
ected reduction in 30-day cardiac mortality seen with
ivalirudin in the HORIZONS-AMI (Harmonizing Out-
omes with Revascularization and Stents in Acute Myocar-
ial Infarction) trial was almost exclusively driven by a
eduction in major bleeding, despite a greater occurrence of
cute stent thrombosis (17). Of note, bivalirudin was not
sed in the Mayo Clinic experience.
Manual thrombectomy aspiration catheters have become
popular tool in the management of thrombotic lesions and
s an adjunct to primary PCI, mainly because of simplicity,
ase of use, and randomized data supporting these catheters.
recent meta-analysis showed significant improvement in
nal TIMI flow, higher myocardial blush grade, less distal
mbolization, and lower mortality with use of manual
spiration thrombectomy (18). The TAPAS (Thrombus
spiration during Percutaneous coronary intervention in
cute myocardial infarction Study), with the largest sample
ize (n  1,071), showed decreased 1-year mortality and
as published in 2008—2 years after the end of the DES
eriod of the Mayo Clinic report, possibly explaining the
ow use of aspiration thrombectomy (19). Interestingly,
heolytic thrombectomy was the preferred strategy in the
ayo Clinic during the studied time period. The Angiojet
evice was approved in the late 1990s and at the time was
onsidered an effective tool for intracoronary thrombus
anagement. However, this technique lost its appeal and
ecame a niche device after the publication of the AIMI
AngioJet Rheolytic Thrombectomy In Patients Undergo-
ng Primary Angioplasty for Acute Myocardial Infarction)
rial, which showed no differences in infarct size or ST-
egment resolution and increased mortality with rheolytic
hrombectomy (20).
The Mayo Clinic report provides reassurance regarding
he use of stents, either BMS or DES, in thrombus-
ontaining lesions, and this is a major contribution of the
tudy. Major adverse cardiac events were significantly re-
uced in the BMS and DES eras in comparison with the
arly stent era. Interestingly, the survival—free of MACE
nd target lesion revascularization—curves at 4 years
howed an intriguing difference in shape between patientsreated in the DES and BMS eras. Initial outcomes seemed
o be improved during the DES era, with a late attrition
fter 2 years. Unfortunately, the current study cannot
nswer whether this finding was a consequence of late stent
hrombosis, but it remains a possibility, considering that
atients were treated before the introduction of prolonged
ual antiplatelet therapy (9).
Interventional cardiology is constantly evolving, with
apidly changing practices. Future studies will hopefully
etermine the effect of widespread use of manual aspiration
hrombectomy and the optimal antithrombotic strategy for
he management of challenging thrombotic lesions. At least
e know that stents seem to be safe in this setting, but the
hrombus issue will continue to stick for the time being.
cknowledgments
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